The HPLC-MS determination of pharmacokinetic parameters of morpholinium 2-((4-(2-methoxyphenyl)-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)thio)acetate

Abstract

Aim. To study pharmacokinetic parameters of the potential active pharmaceutical ingredient (API) morpholinium 2-((4-(2-methoxyphenyl)-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)thio)acetate in the blood plasma of rats when administered intraperitoneally. Results and discussion. The HPLC-MS method of determination of morpholinium 2-((4-(2-methoxy)-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)thio)acetate in the blood plasma of non-linear rats has been adopted to study of pharmacokinetic parameters of the compound. It has been proven that high levels of API extraction from the blood plasma when using methanol for protein precipitation were observed. The measurement of the concentration of the drug substance studied in the blood plasma at different time intervals after injection allowed us to plot the pharmacokinetic curve and calculate the pharmacokinetic parameters. Experimental part. The Agilent 1260 Infinity liquid chromatography system consisted of a degasser, binary pump, autosampler, column thermostat, diode-matrix detector, single-quadrupole mass spectrometric detector (Agilent 6120). The pharmacokinetic study was performed in sexually mature white nonlinear rats of two sexes. The active pharmaceutical ingredient morpholinium 2-((4-(2-methoxy)-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)thio)acetate, was administered in the isotonic solution intraperitoneally in the dose of 50 mg/kg. Conclusions. The pharmacokinetic curve has been plotted, and the pharmacokinetic parameters of morpholinium 2-((4-(2-methoxy)-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)thio)acetate in the blood plasma when administered intraperitoneally have been calculated.

Keywords

• liquid chromatography
• triazoles
• pharmacokinetics